The Deep Vein Thrombosis Market Size is valued at 958.11 Million in 2022 and is predicted to reach 1343.86 Million by the year 2031 at a 4.0 % CAGR during the forecast period for 2023-2031.
Deep vein thrombosis (DVT) is a serious condition that occurs when clots forms in the deep veins of the body. The most dangerous complication of deep vein thrombosis is pulmonary embolism (PE), which can either be asymptomatic or symptomatic. Surgery and pregnancy are the major risk factors associated with deep vein thrombosis. Pregnancy increase hormone level and slower blood flow lead to expansion of uterus and restrict blood flowing back from lower extremities responsible for deep vein thrombosis. Diagnosis of deep vein thrombosis can be made with blood tests such as D-dimer test and imaging tests such as Doppler ultrasound (Duplex), contrast venogram, magnetic resonance imaging (MRI), and computer tomography (CT). There are four types of treatments for deep vein thrombosis include anticoagulant, thrombolytic therapy, IVC filters (Vein Filters), and Stents. Anticoagulant such as unfractionated heparin, low molecular weight heparin (enoxaparin/ Lovenox, dalteparin/Fragmin, or tinzaparin/Innohep, fondaparinux/Arixtra or desirudin/Iprivask), warfarin (Coumadin and Jantoven) are the primary treatment deep vein thrombosis. Thrombolytic therapy such as tissue plasminogen activator agents (tPA) can help to dissolve the blood clot. IVC filters (Vein Filters), also known as “Greenfield filters,” is an umbrella-shaped device that is placed into the large vein, which traps blood clots and prevents deep vein thrombosis and pulmonary embolism. Stents are metal meshwork tubes that are placed into a vein to keep them open.
Deep Vein Thrombosis market is segmented into Treatement, Distribution channel and Region. On the basis of Treatment, market is segmented into Clot Busters, Blood Thinners, Inferior Vena Cava Filters, Compression Stockings, Others, on the other side, By Distribution Channel, market is devided into Retail Pharmacy, Hospital Pharmacy, and E-commerce. Regionally, market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Almost one-half million patients are hospitalized for venous thromboembolism (consist of deep vein thrombosis and pulmonary embolism) each year in the United States. In Europe, there are 544,000 venous thromboembolism related death every year. Venous thromboembolism can cause a significant global economic burden. Various diagnostic tests and treatment, prolonged hospital stay, and follow-up care can be extremely costly; for instance estimated medical cost for venous thromboembolism in the U.S is $5-10 billion per year. In U.K venous thromboembolism related cost is 750 million per year. In Australia, venous thromboembolism related costs are estimated at 1.72 billion a year. In June 2017, U.S. FDA (Food and Drug Administration) approved betrixaban (Portola) for the adult with venous thromboembolism (VTE). Pentasaccharides such XARELTO are novel anticoagulants may be preferred over standard therapy due to few drug interactions and no need for frequent monitoring or re-dosing.
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 958.11 Million |
|
Revenue Forecast In 2031 |
USD 1343.86 Million |
|
Growth Rate CAGR |
CAGR of 4.0 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Treatment, By Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Sandoz Inc. Teva Pharmaceuticals USA, Inc. Sanofi-Aventis U.S. LLC, Baxter International Inc., West-Ward Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc. Abbott Laboratories, Bristol-Myers Squibb Company, Pfizer, Daiichi Sankyo Co. Ltd., Medtronic plc, Johnson & Johnson, and others. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Deep Vein Thrombosis Market Snapshot
Chapter 4. Global Deep Vein Thrombosis Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
4.9. Clinical Trial/Pipeline Analysis
Chapter 5. Market Segmentation 1: By Treatment Estimates & Trend Analysis
5.1. By Treatment & Market Share, 2019 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By Treatment:
5.2.1. Clot Busters
5.2.2. Blood Thinners
5.2.3. Inferior Vena Cava Filters
5.2.4. Compression Stockings
5.2.5. Others
Chapter 6. Market Segmentation 2: By Distribution Channel Estimates & Trend Analysis
6.1. By Distribution Channel & Market Share, 2019 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By Distribution Channel:
6.2.1. Hospital Pharmacy
6.2.2. Retail Pharmacy
6.2.3. Online Pharmacy
Chapter 7. Deep Vein Thrombosis Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Deep Vein Thrombosis Market revenue (US$ Million) estimates and forecasts By Treatment, 2023 - 2031
7.1.2. North America Deep Vein Thrombosis Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2023 - 2031
7.1.3. North America Deep Vein Thrombosis Market revenue (US$ Million) estimates and forecasts by country, 2023 - 2031
7.2. Europe
7.2.1. Europe Deep Vein Thrombosis Market revenue (US$ Million) By Treatment, 2023 - 2031
7.2.2. Europe Deep Vein Thrombosis Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2023 - 2031
7.2.3. Europe Deep Vein Thrombosis Market revenue (US$ Million) by country, 2023 - 2031
7.3. Asia Pacific
7.3.1. Asia Pacific Deep Vein Thrombosis Market revenue (US$ Million) By Treatment, 2023 - 2031
7.3.2. Asia Pacific Deep Vein Thrombosis Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2023 - 2031
7.3.3. Asia Pacific Deep Vein Thrombosis Market revenue (US$ Million) by country, 2023 - 2031
7.4. Latin America
7.4.1. Latin America Deep Vein Thrombosis Market revenue (US$ Million) By Treatment, (US$ Million)
7.4.2. Latin America Deep Vein Thrombosis Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2023 - 2031
7.4.3. Latin America Deep Vein Thrombosis Market revenue (US$ Million) by country, (US$ Million) 2023 - 2031
7.5. Middle East & Africa
7.5.1. Middle East & Africa Deep Vein Thrombosis Market revenue (US$ Million) By Treatment, (US$ Million)
7.5.2. Middle East & Africa Deep Vein Thrombosis Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2023 - 2031
7.5.3. Middle East & Africa Deep Vein Thrombosis Market revenue (US$ Million) by country, (US$ Million) 2023 - 2031
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Sandoz Inc.
8.2.2. Teva Pharmaceuticals USA, Inc.
8.2.3. Sanofi-Aventis U.S. LLC,
8.2.4. Baxter International Inc.,
8.2.5. West-Ward Pharmaceuticals,
8.2.6. Boehringer Ingelheim Pharmaceuticals, Inc.
8.2.7. Abbott Laboratories,
8.2.8. Bristol-Myers Squibb Company,
8.2.9. Pfizer,
8.2.10. Daiichi Sankyo Co. Ltd.,
8.2.11. Medtronic plc,
8.2.12. Johnson & Johnson,
8.2.13. others
Global Deep Vein Thrombosis Market Outlook By Treatment
Global Deep Vein Thrombosis Market Outlook By Distribution Channel
Global Deep Vein Thrombosis Market Outlook By Region
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
